Efficacy and safety of ipragliflozin in Japanese patients with type 2 diabetes and inadequate glycaemic control on sitagliptin.

Kohei KakuTakashi KadowakiYutaka SeinoTaro OkamotoMasayoshi ShirakawaAsako SatoEdward A O'NeillSamuel S EngelKeith D Kaufman

Published in: Diabetes, obesity & metabolism (2021)

Ipragliflozin 50 mg once daily added on to sitagliptin 50 mg once daily monotherapy provided significant improvement in glycaemic control and was generally well tolerated in Japanese patients with T2D. ClinicalTrials.gov: NCT02577003, NCT02564211.

Keyphrases

type diabetes
physical activity
open label
combination therapy
randomized controlled trial
clinical trial
study protocol